Compare Alliant Energy Corporation (LNT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Alliant Energy Corporation trades at $72.67 (market cap $19.10B), while Vertex Pharmaceuticals Incorporated trades at $484.5 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 6.4× Alliant Energy Corporation's market cap, and Alliant Energy Corporation pays a 2.89% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| LNT | VRTX | |
|---|---|---|
Market Cap | $19.10B | $121.95B |
Sector | Utilities | Health |
52-Week High | $78.03 | $529.59 |
52-Week Low | $63.62 | $366.54 |
Enterprise Value | $30.83B | $116.69B |
Dividend Yield | 2.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LNT trades at $73.96, down 1.16% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $78.50. The company reported Q1 2026 EPS of $0.82, beating expectations, and maintains a net income margin of 18.58%. Recent news highlights its $13.4 billion clean energy investment plan aimed at capitalizing on data center demand growth.
The outlook for LNT is positive, supported by steady earnings growth, a strong dividend yield, and strategic investments in renewable energy. Key risks include rising debt levels and exposure to regulatory changes in the utilities sector. Analyst sentiment is bullish with no sell ratings, indicating confidence in the company's long-term growth trajectory.
Vertex Pharmaceuticals (VRTX) trades at $480.51, down 1.06% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a 35.51% net income margin and robust cash flow, though it faces a recent earnings miss. A major $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio, adding potential for significant future revenue growth.
The outlook remains positive with an 85.71% analyst buy rating and a $538 consensus price target, implying 12% upside. Key risks include integration challenges from the acquisition and reliance on cystic fibrosis treatments. Earnings growth and successful pipeline execution are critical catalysts for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
